J Shen1, R H Yang2, Y C Zhang3, A J Liao1, Z G Liu1, W Yang1. 1. Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110004, China. 2. Department of Blood Transfusion, China Medical University First Hospital, Shenyang 110001, China. 3. Hematology Laboratory, Shengjing Hospital of China Medical University, Shenyang 110004, China.
Abstract
Objective: In this study, we aimed to determine the change and clinical significance of serum level Apo A1 in MM patients. Methods: In total, 412 multiple myeloma patients were examined. SPSS 22.0 was used for data analysis. Correlation analysis was performed using linear correlation or Spearman rank correlation coefficients. Measurement data were analyzed with the t-test, Mann-Whitney U-test, or oneway analysis of variance (ANOVA) . Used the ROC curve to calculate the cutoff value and compared the OS and PFS between high Apo A1 subgroup and low Apo A1 subgroup with Kaplan-Meier survival analysis. Results: Our study showed that value of Apo A1 in the patient group was lower than that in the control group (0.89 g/L vs 1.24 g/L, P<0.05) . We found that Apo A1 dynamically changed with different MM stages. As it was increased when the disease was in remission, and decreased after disease in progression. According the result of multivariate analysis Apo A1 reduction become the independent risk factors of MM. On the basis of Kaplan-Meier survival analysis between high Apo A1 subgroup and low Apo A1 subgroup, we found higher Apo A1 patienta had longer OS rate and PFS. Conclusions: Apo A1 is a useful biomarker of tumor burden and a prognostic factor of multiple myeloma.
Objective: In this study, we aimed to determine the change and clinical significance of serum level Apo A1 in MM patients. Methods: In total, 412 multiple myelomapatients were examined. SPSS 22.0 was used for data analysis. Correlation analysis was performed using linear correlation or Spearman rank correlation coefficients. Measurement data were analyzed with the t-test, Mann-Whitney U-test, or oneway analysis of variance (ANOVA) . Used the ROC curve to calculate the cutoff value and compared the OS and PFS between high Apo A1 subgroup and low Apo A1 subgroup with Kaplan-Meier survival analysis. Results: Our study showed that value of Apo A1 in the patient group was lower than that in the control group (0.89 g/L vs 1.24 g/L, P<0.05) . We found that Apo A1 dynamically changed with different MM stages. As it was increased when the disease was in remission, and decreased after disease in progression. According the result of multivariate analysis Apo A1 reduction become the independent risk factors of MM. On the basis of Kaplan-Meier survival analysis between high Apo A1 subgroup and low Apo A1 subgroup, we found higher Apo A1 patienta had longer OS rate and PFS. Conclusions: Apo A1 is a useful biomarker of tumor burden and a prognostic factor of multiple myeloma.
Authors: Rachel A Egler; Yiting Li; Tu Anh T Dang; Tricia L Peters; Eastwood Leung; Shixia Huang; Heidi V Russell; Hao Liu; Tsz-Kwong Man Journal: Proteomics Clin Appl Date: 2011-09-07 Impact factor: 3.494
Authors: Feng Su; Kathy R Kozak; Satoshi Imaizumi; Feng Gao; Malaika W Amneus; Victor Grijalva; Carey Ng; Alan Wagner; Greg Hough; Gina Farias-Eisner; G M Anantharamaiah; Brian J Van Lenten; Mohamad Navab; Alan M Fogelman; Srinivasa T Reddy; Robin Farias-Eisner Journal: Proc Natl Acad Sci U S A Date: 2010-11-01 Impact factor: 11.205
Authors: Shaji K Kumar; Natalie S Callander; Melissa Alsina; Djordje Atanackovic; J Sybil Biermann; Jorge Castillo; Jason C Chandler; Caitlin Costello; Matthew Faiman; Henry C Fung; Kelly Godby; Craig Hofmeister; Leona Holmberg; Sarah Holstein; Carol Ann Huff; Yubin Kang; Adetola Kassim; Michaela Liedtke; Ehsan Malek; Thomas Martin; Vishala T Neppalli; James Omel; Noopur Raje; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Donna Weber; Joachim Yahalom; Rashmi Kumar; Dorothy A Shead Journal: J Natl Compr Canc Netw Date: 2018-01 Impact factor: 11.908
Authors: Maryam Zamanian-Daryoush; Daniel Lindner; Thomas C Tallant; Zeneng Wang; Jennifer Buffa; Elizabeth Klipfell; Yvonne Parker; Denise Hatala; Patricia Parsons-Wingerter; Pat Rayman; Mohamed Sharif S Yusufishaq; Edward A Fisher; Jonathan D Smith; Jim Finke; Joseph A DiDonato; Stanley L Hazen Journal: J Biol Chem Date: 2013-05-17 Impact factor: 5.157